Can human cardiosphere-derived cells improve function in late-stage DMD?

Specialists have reported new findings on the safety and efficacy of CAP-1002, an allogeneic cardiosphere-derived cell population, in mitigating deterioration of upper limb and cardiac function in patients with advanced Duchenne muscular dystrophy (DMD).

Presenting at the WMS 2021 virtual congress, Professor Craig McDonald from the University of California, Davis, USA, summarised the findings from a multicenter, randomized, double-blinded, placebo controlled clinical trial called the Halt Cardiomyopathy Progression-2 (HOPE-2) trial.